The Neurology Center of Southern California
6010 Hidden Valley Road, Suite 200
Carlsbad, CA. 92011
Phone: (760) 631-3000 | Fax: (760) 631-3016



GREGORY ARAM SAHAGIAN, M.D.

EDUCATION

Columbia University
School of Engineering and Applied Science, New York City, NY 07/1987-06/1991
B.S. in Chemical Engineering

Albert Einstein College of Medicine, Bronx, NY 08/1991-06/1995
M.D.

NYU Langone Hospital – Long Island, Mineola, NY 06/1995-06/1996
Internship, Internal Medicine

University of California, San Diego, San Diego, CA 07/1996-06/1998
Residency, Neurology

University of California, San Diego, San Diego, CA 07/1998-06/1999
Chief Resident, Neurology

University of California, San Diego, San Diego, CA 07/1999-06/2000
Fellowship, Neuromuscular diseases

PROFESSIONAL EXPERIENCE

Chief Scientific Officer, Profound Research 2023 – Present

Neurologist, Private Group Practice 2000 – Present
North County Neurology Associates DBA The Neurology Center, Carlsbad, CA
CEO – 2003 -Present
- Lab Medical Director, AANEM Accredited EMG lab with Exemplary Status 2013 – 2025
- Principal Investigator/Sub-Investigator 2000 – Present

Scripps Healthcare
- Medical Director of Neurosciences 2018 - Present
  - system wide medical director for neurosciences (Neurology, Neurosurgery, Endovascular, PM&R)

Scripps Memorial Hospital Encinitas
Chief of Neurology 2016 - 2025
Peer Review Committee 2015 - 2025
Credentials Committee 2016 - 2025

San Diego Physician Medical Group - Optum
Board Member 2018 - Present

Tri-City Medical Center, Oceanside, California,
Medical Director, Neurology 2016 - 2023
Chief of Neurology 2002 - 2015
Chairman, Department of Medicine 2003 - 2005

UC San Diego Health

- Assistant Clinical Professor, Voluntary UCSD Department of Neurosciences 2000 – Present
- Board Member, Clinically Integrated Network 2015 – Present
- Outreach Services Director 2016 – 2018
- UCSD Health Physician Network Quality Committee 2016 – 2019

UHS Southern California Medical Education Consortium

Faculty ACGME Training Program 2019 - Present

Rady's Children Hospital

- Muscular Dystrophy Association Clinic 2000 - 2010

Myasthenia Gravis Foundation of California

- Medical Advisory Board Member 2013 - Present

Intraneuron, LLC

- Co-founder 2013 - Present
- Neuroscience focused software development
- Voice-recognition cognitive screening software

Alzheimer's Association Board Member 2024 – Present

Consulting Advisory Boards

- Argenx UCB Pharma
- Alexion
- Amgen
- Biogen
- Avilar Therapeutics
- Cartesian
- Immunoxant
- Huma

LICENSURE

California Medical License Active

CERTIFICATIONS

American Board of Psychiatry and Neurology- Neurology 2001 ACTIVE
American Board of Psychiatry and Neurology- Neuromuscular Medicine 2012 ACTIVE
American Board of Electrodiagnostic Medicine 2002 ACTIVE
The Joint Commission Accredited with National Quality Approval - Gold Seal of Approval
AANEM Accredited EMG lab with Exemplary Status

AWARDS

Top Doctor Award
San Diego ■2007 ■2013 ■ 2014 ■ 2015 ■ 2016 ■ 2017■ 2020 ■ 2021 ■ 2023 ■ 2024 ■ 2025
Golden Neuron award for most outstanding Neurology Resident,
University of California, San Diego 1999

PROFESSIONAL SOCIETIES

American Academy of Neurology	
American Association of Neuromuscular and Electrodiagnostic Medicine	
California State Liaison 2008- Present	
Young Physician Section representative to the CMA	2005-2009
California Medical Association	
Young Physician Section Delegate to the AMA	2005-2009
San Diego Neurologic Society Program Chairman	2001-2004
San Diego County Medical Society	
American Medical Association	
Society for Neuroscience	

HOSPITAL AFFILIATIONS

Tri-City Medical Center, Oceanside, California, Refer & Follow	06/2000–Present
Scripps Memorial Hospital, Encinitas, California, Courtesy Privileges	08/2000–Present
Scripps Memorial Hospital, La Jolla, California, Affiliate No Privileges	05/2015–Present
Scripps Mercy Hospital, Chula Vista, California, Affiliate No Privileges	07/2022–Present
Palomar Medical Center, Escondido, California, Affiliate No Privileges	10/2012–Present
Pomerado Medical Center, Poway, California, Affiliate No Privileges	10/2012–Present
Rady Children's Hospital, San Diego, CA Hospital Affiliate No Privileges	02/2009–03/2026
Temecula Valley Hospital, Temecula, California	03/2021-04/2026

PUBLICATIONS

- Chahin, Nizar, **Sahagian, Gregory**, Feinberg, Marc H., Stewart, C. Andrew, Jewell, Christopher M., Kurtoglu, Metin, Miljković, Miloš D., Vu, Tuan, Mozaffar, Tahseen, Howard, James F. Jr. Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis https://doi.org/10.1002/acn3.70167

- Vu, T., Durmus, H., Rivner, M., **Sahagian, G.** *et al.* BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial. *Nat Med* (2026). https://doi.org/10.1038/s41591-025-04171-y

- C. H.Gibbons, T.Levine, C. H.Adler, **G. Sahagian**, et al., "Cutaneous Phosphorylated Alpha-Synuclein in Lewy Body Dementia," Annals of Clinical and Translational Neurology (2025): 1–11, https://doi.org/10.1002/acn3.70291.
- Allen J, Lin J, Basta I, **Sahagian G**, et al. Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial, The Lancet Neurology, 23, 1013-1024
- Gibbons CH, Levine T, Adler C, **Sahagian G**, et al. Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies. JAMA. 2024;331(15):1298–1306. doi:10.1001/jama.2024.0792
- Wingerchuk, D.M., Fujihara, K., Palace, J., Berthele, A., Levy, M., **Sahagian, G.**, Kim, H.J., Nakashima, I., Oreja-Guevara, C., Wang, K.-C., Miller, L., Shang, S., Sabatella, G., Yountz, M., Pittock, S.J. and PREVENT Study Group (2021), Long-Term Safety and Efficacy of Eculizumab in Aquaporin-4 IgG-Positive NMOSD. Ann Neurol, 89: 1088-1098. https://doi.org/10.1002/ana.26049

- Dubois, J., Duffy, J.G., Field, R.M., Koch, E.M., Aghajan, Z.M., Miller, N., Perdue, K.L., **Sahagian, G**., Taylor, M. A functional neuroimaging biomarker of mild cognitive impairment using TD-fNIRS. npj Dement. 1, 14 (2025). https://doi.org/10.1038/s44400-025-00018-y

- Habib, A.A., Claeys, K.G., Bril, V., Hussain, Y., Gwathmey, K., **Sahagian, G.,** Cortés-Vicente, E., Brauer, E., Gelinas, D., Sumbul, A., Jimenez, R.H., Hristova, D., Masschaele, D., Mantegazza, R., Meisel, A., Attarian, S. and (2025), ADAPT NXT: Fixed Cycles or Every-Other-Week IV Efgartigimod in Generalized Myasthenia Gravis. Ann Clin Transl Neurol. https://doi.org/10.1002/acn3.70051

- Tuan Vu, Hacer Durmus Tekce, Michael Rivner, Sheetal Shroff, Thomas Ragole, Bennett Myers, Mamatha Pasnoor, George Small, Chafic Karam, Mithila Vullaganti, Amanda Peltier, **Gregory Sahagian**, Marc Feinberg, Carolina Barnett Tapia, Zaeem Siddiqi, Christopher Jewell, Metin Kurtoglu, Hafsa Kamboh, Milos Miljkovic, Tahseen Mozaffar, James Howard. (2025, Apr 5-9). Efficacy and Safety of Autologous BCMA-directed mRNA CAR T-Cell Therapy in Generalized Myasthenia Gravis: Results from a Phase 2b Randomized Placebo-controlled Trial. 2025 American Academy of Neurology Annual Meeting, San Diego, CA. https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-005230.html

- Kelly Gwathmey, Vera Bril, Ali A. Habib, Kristl G. Claeys, Yessar Hussain, **Gregory Sahagian**, Elena Cortés-Vicente, Edward Brauer, Jeff Guptill, Deborah Gelinas, Li Liu, Rosa H. Jimenez, Delphine Masschaele, Renato Mantegazza, Andreas Meisel, Fang Sun, Shahram Attarian. (2025, Apr 5-9). Fixed Cycle and Every-Other-Week Dosing of Intravenous Efgartigimod for Generalized Myasthenia Gravis: Part B of ADAPT NXT. 2025 American Academy of Neurology Annual Meeting, San Diego, CA. https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-002917.html

- Bruce Seligmann, Monica Hernandez, Megan Opichka, Salvatore Camiolo, Joanne Yeakley, Zhoutao Chen, **Gregory Sahagian**. (2025, Apr 5-9). Multi-omic Liquid Biopsy Fingerstick Blood Test Platform for Neurological Disorders: Classification of Alzheimer's Disease, Parkinson's Disease and Myasthenia Gravis. 2025 American Academy of Neurology Annual Meeting, San Diego, CA. https://index.mirasmart.com/AAN2025/PDFfiles/AAN2025-004737.html

- Bruce Seligmann, Salvatore Camiolo, Monica Hernandez, Joanne Yeakley, **Gregory Sahagian**, Joel McComb; Molecular Gene Expression Testing to Identify Alzheimer's Disease with High Accuracy from Fingerstick Blood. Journal of Alzheimer's Disease, 11 SEP 2024

- Richard J Nowak, Ari Breiner, Vera Bril, Jeffrey A Allen, Shaida Khan, Todd Levine, Daniel H Jacobs, **Gregory Sahagian**, Zaeem A Siddiqi, Jing Xu, William L Macias, Michael Benatar, ASCEND MG Study Group, Annals of Clinical and Translational Neurology 2024-01-01; Subcutaneous batoclimab in generalized myasthenia gravis: Results from a Phase 2a trial with an open-label extension

- Volkan Granit, Michael Benatar, Tahseen Mozaffar, Nizar Chahin, James F. Howard Jr, Adam D. Slansky, Marc H Feinberg, **Gregory Sahagian**, Tuan Vu, Denise Pereira, Julie Steele, Maria Elena Paredes, Cara Benjamin, Krishna Komanduri, Ali Aamer Habib, Julia Kimberly Fong, Luis De La Cruz, Diana Dimitrova, Manisha Chopra, Kelly Holley, Gabrielle DeMaria, April Tenorio, Naraly Requena, Beverly Mackanzie Brooks, Niraja Suresh, Jessica Farias, Milos D Milijkovic, Metin Kurtoglu, Minhtran Ngo Casi, Adam Chowdhury, Hafsa Kamboh, C Andrew Stewart, Mehmet Tosun, Yufei Shan, Shaji Daniel, Matthew T. Duvernay, Maria Kireeva, Emily English, Christopher M. Jewell, Michael S Singer, Murat V Kalayoglu. The Lancet. Neurology 2023-07-01; Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open – label, non – randomized phase 1b/2a study.

- The Lancet, Neurology 2021-07-01; Safety, efficacy, and tolerability of efgartigimod in parents with generalized myasthenia gravis (ADAPT): a multicentre, randomized, placebo-controlled phase 3 trial.

- Lindsay Olson-Mack, Jessica Burley, Robin Calara, Robert Claycomb, Linda Couts, Mary A Kalafut, K. Jill Libby, Renee Richetts, **Gregory Sahagian**, Jean M Rockwell, Scripps Health, San Diego, CA Who Are We Missing? False Call Rates Decline for Stroke Code Activations During Early Phase of Covid-19 Pandemic Abstract poster ISC meeting 2021

- Phillips G, Muppidi S, **Sahagian G**, Smith G, Huang, D, Campbell D; Conceptualization and Novel Budget Impact Analysis Framework for Treatments of Myasthenia Gravis. Abstract ISPOR 2021

- Smith N, Howard J, **Sahagian G**, Smith G, Silvestri NJ, Hehir M, Leighton T, Jeyakumar S, Phillips GA; Comparative Effectiveness and Safety of Efgartigimod in Generalized Myasthenia Gravis Abstract ISPOR 2021

- Wagner, G., Rosen, J., Vignisson, V., **Sahagian, G.,** Haase-Alasantro, L;.A pilot study investigating a voice recognition cognitive screening tool for detection of neuropsychological changes; Abstract AAIC 2021

- Wagner, G., Rosen, J., Holguin, G., Frishberg, B., Wang, A., **Sahagian, G.,** Haase-Alasantro, L. (2016). Clinical Assessment of Posterior Cortical Atrophy. Poster presented at the National Academy of Neuropsychology Conference, Seattle, WA.

- Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. N Engl J Med. 2014 Jan 23;370(4):322-33

- Liu E, Schmidt ME, Margolin R, Sperling R, Koeppe R, Mason NS, Klunk WE, Mathis CA, Salloway S, Fox NC, Hill DL, Les AS, Collins P, Gregg KM, Di J, Lu Y, Tudor IC, Wyman BT, Booth K, Broome S, Yuen E, Grundman M, Brashear HR; Bapineuzumab 301 and 302 Clinical Trial Investigators. Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials Neurology. 2015 Aug 25;85(8):692-700

- Morello CM, Leckband SG, Stoner CP, Moorhouse DF, **Sahagian GA:** Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch Intern Med 1999 Sep 13; 159(16): 1931-7

RESEARCH ACTIVITIES

Neuromuscular

- "Epidermal Nerve Fiber Analysis in Amyotrophic Lateral Sclerosis", Principal Investigator, 2009-2015

- PrecisionMed 4800: A single or multiple visit protocol for collection of DNA/RNA/SERUM/PLASMA/CSF in Amyotrophic Lateral Sclerosis and related disorders." Principal Investigator, 2012

- A Phase 2, Multicenter, Randomized, Double-Blind. Placebo-Controlled Study to evaluate the Safety, Tolerability, and Preliminary Efficacy of RA101495 in Subjects with Generalized Myasthenia Gravis. Sub-Investigator, 2017-2018

- ARGX-113-1802. A Phase 2 Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Principal Investigator – 2020

- ARGX-113-1902. Open-label Extension of the ARGX-113-1802 Trial to Investigate the Long-term Safety, Tolerability, and Efficacy of Efgartigimod PH20 SC in Patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Principal Investigator– 2020

- RVT-1401-2002. A Phase 2a, Multicenter, Randomized, Double Blind, Placebo-Controlled Study with an Open-Label Extension of RVT-1401 in Myasthenia Gravis Patients. Principal Investigator – 2020

- ARGX-113-1704. A Randomized, Double Blind, Placebo-Controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy, Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis Having Generalized Muscle Weakness. Principal Investigator – 2019

- ARGX-113-1705. A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized Muscle Weakness. Principal Investigator – 2020

- ARGX-113-2001. A Phase 3, Randomized, Open-Label, Parallel-Group Study to Compare the Pharmacodynamics, Pharmacokinetics, Efficacy, Safety, Tolerability, and Immunogenicity of Multiple Subcutaneous Injections of Efgartigimod PH20 SC With Multiple Intravenous Infusions of Efgartigimod in Patients With Generalized Myasthenia Gravis – 2021

- ARGX-113-2002. A Long-term, Single-Arm, Open-label, Multicenter Phase 3 Study to Evaluate the Safety and Tolerability of Multiple Subcutaneous Injections of Efgartigimod PH20 SC in Patients With Generalized Myasthenia Gravis – 2021

- Synuclein-One Study: A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants with Generalized Myasthenia Gravis (gMG) IMVT-1401-3101, IND: 141885. Principle Investigator-2021

- ARGX-113-2003. A Phase 3b, Randomized, Open-label, Parallel-Group Study to Evaluate Different Dosing Regimens of Intravenous Efgartigimod to Maximize and Maintain Clinical Benefit in Patients With Generalized Myasthenia Gravis – 2022

- MG-001. Autologous T-Cells Expressing a Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) in Patients with Generalized Myasthenia Gravis – 2022

- NMD670-02-0002: A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 over 21 Days in Adult Patients with AChR/MuSK-Ab+ Myasthenia Gravis. Sub Investigator – 2023

Alzheimer's Disease

- GAL-INT-11 "A randomized double blind placebo-controlled trial to evaluate the efficacy and safety of Galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probably Alzheimer's disease." Sub-Investigator, 2001

- TVP1012-A001-201- A 1-Year, double-blind, randomized, placebo-controlled study of Ragasiline 1 mg and 2 mg added to Aricept 10 mg daily in patients with mild to moderate dementia of the Alzheimer's type." Sub-Investigator, 2005

- VP-AD-301 "A Double-Blind Placebo-Controlled Study of VP4896 for the Treatment of Mild to Moderate Alzheimer's Disease." Sub-Investigator, 2006

- PRX-03140 "A Randomized, Double-Blind, Placebo Controlled, Phase IIa Study to Assess the Short-Term Effects of PRX-03140 Alone and in Combination with Donepezil in Subjects with Mild Alzheimer's Disease." Sub-Investigator, 2006

- ELN115727-301 & 302 "A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Efficacy and Safety Trial of Bapineuzumab (AA-001, ELN115727 in Patients with Mild to Moderate Alzheimer's Disease who are Apo lipoprotein Eε4 Non-Carriers (301) or Non-Carriers (302)." Sub-Investigator, 2008

- ELN115727-351 "A Phase 3 Extension, Multicenter, Double-Blind, Long Term Safety and Tolerability Treatment Trial of Bapineuzumab (AAB-001, ELN115727) in Subjects with Alzheimer's Disease Who Participated in Study ELN115727-301 or in Study ELN115727-302." Sub-Investigator, 2009

- AAB-001-SC-ALZ-2003 "A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multi-Center, Biomarker, Safety, and Pharmacokinetic Study of Bapineuzumab (AAB-001) Administered Subcutaneously at Monthly Intervals in Subjects with Mild to Moderate Alzheimer's Disease." Sub-Investigator, 2010

- 14862A "Randomized, double-blind, parallel-group, placebo-controlled, fixed-dose study of Lu AE58054 in patients with mild-moderate Alzheimer's disease treated with donepezil." Sub-investigator, 2015

- TempO-Seq Whole Blood Assay for Evaluation of Progression and Outcome in Neurodegenerative and other Diseases. Principal investigator, 2021

- JIG-MC-LAKC. Assessment of safety and efficacy measured by amyloid reduction of LY3372993 in early symptomatic AD. Sub-Investigator – 2022

- ACU193-201: A Phase 2/3 Double-Blind, Randomized, Placebo-Controlled Adaptive Design Trial to Evaluate the Efficacy and Safety of Intravenous ACU193 in Early Alzheimer's Disease. Sub Investigator – 2023

Epilepsy

- E2080-A001-301 "A Double-Blind, Placebo-Controlled, Parallel-Group Study of Rufinamide Given as Adjunctive Therapy in Patients with Refractory Partial Seizures". Sub Investigator, 2006

Migraine

- 191622-037-00 "A multicenter, double-blind, randomized, placebo-controlled, parallel group study of BOTOX® (Botulinum Toxin Type A) purified neurotoxin complex for the prophylactic treatment of migraine headaches in the episodic migraine population." Sub-Investigator, 2001

- 191622-038-01 "A multicenter, double-blind, randomized, placebo-controlled, parallel group study of BOTOX® (Botulinum Toxin Type A) purified neurotoxin complex for the prophylactic treatment of headaches in the chronic headache population." Sub-Investigator, 2001

- CAPSS-155 "A comparison of the efficacy and safety of TOPAMAX® (Topiramate) tablets versus placebo for the prophylaxis of migraine." Sub-Investigator, 2001

- MT 100-308 "A double blind, placebo-controlled, study to evaluate the safety and efficacy of MT 100 versus over-encapsulated Sumatriptan in subjects with acute migraine attacks." Sub-Investigator, 2001

- MT100-402 – "A Double Blind, Randomized Placebo-Controlled, Study to Evaluate the Safety and Efficacy of MT 100 for the Treatment of Migraine in Subjects Who Are Intolerant to 5-HT Agonists or Have Cardiovascular Risk Factors." Sub-Investigator, 2001

- MT100-401A – "A Double Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety and Efficacy of a Two Tablet Dose of MT 100 for Treatment of Migraine in Imitrex® None responders." Sub-Investigator, 2001

- MT 300-302 – "A Randomized-Double-Blind, Placebo Controlled Evaluation of the Safety and Efficacy of MT 300 in the Acute Treatment of Migraine." Sub-Investigator, 2003

- SUM40298 – "A Randomized, Double-Blind, Placebo-Controlled, Single Attack, Parallel-Group Evaluation of the Efficacy of Sumatriptan 50mg Tablets versus Placebo in the Treatment of Self-Described and/or Physician-Diagnosed Sinus Headaches that Meet International Headache Society (HIS) Criteria for Migraine Headache." Sub-Investigator, 2003

- VML251/00/02 – "A Double-Blind, Placebo-Controlled, Three-Way Crossover Clinical Study to Assess the Safety and Efficacy of Two Dose Regimens of Frovatriptan, Compared with Placebo, in Preventing Menstrually Associated Migraine (MAM) Headaches." Sub-Investigator, 2002

- 311CUS/0022 "A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Trial to Evaluate Early Efficacy and Tolerability of Zolmitriptan (Zomig) Nasal Spray in the Acute Treatment of Adult Subjects with Migraine." Sub-Investigator, October 2002

- MT300-401 "A Multicenter Randomized, Single-Blind, Evaluation of Three Injectable Anti-Migraine Drugs." Sub-Investigator, February 2003

- 3420AG1 – "Program to Assess Treatment Strategies: A Botox Observational Program." – Sub Investigator, 2003

- CL1776-005 – "A Phase 2 Safety and Efficacy Study of NPS 1776 for the Acute Treatment of Migraine Headaches." Sub Investigator, 2004

- 001 – "A Randomized, Evaluator-Masked Trial to Evaluate the Efficacy of Botox Compared with Depakote in Migraine Prevention." Sub Investigator, 2004

- MT400-303 "An Open-label, Repeat Dose Study of the Safety of Combo Formulation in the Treatment of Multiple Episodes of Acute Migraine over 12 Months." Sub-Investigator, 2004

- MT400-301 (POZEN) "A Double-Blind, Multicenter, Randomized, Placebo-Controlled Single Dose Study To Evaluate The Safety And Efficacy Of Trexima In The Acute Treatment Of Migraine Headaches." Sub-Investigator, 2004

- 065-00 (Maxalt) "A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10-mg Tablet Administered Early During a Migraine Attack While the Pain is Mild."Sub-Investigator, 2004

- VML251-3MRM/02 "A double-blind, placebo-controlled, parallel group study, with an open-label extension phase, to assess the efficacy, tolerability and safety of oral frovatriptan in the prevention of menstrually related migraine (MRM) headaches in a "difficult to treat" population." Sub-Investigator, 2005

- E2007-A001-210- A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group Study to Evaluate the Efficacy and Safety of E2007 in Migraine Prophylaxis." Sub-Investigator, 2005

- A Single-Center, Double-Blind Comparison of BOTOX® (Botulinum Toxin Type A) and DEPAKOTE® for the Prophylactic Treatment of Migraine Headaches- Pilot Study." Sub-Investigator, 2005

- "A Single-Center, Double-Blind Comparison of Botox and Topiramate for the Prophylactic Treatment of Chronic Migraine Headache." Sub-Investigator, 2005

- 1602 "A Multi-Center, Randomized, Single-Blind, Controlled Study to Obtain Preliminary Safety and Efficacy Data for ONS Treatment of Chronic Migraine Headache." Sub-Investigator, 2005

- 191622-079/080 "A Multicenter Study Evaluating the Efficacy and Safety of Botox Purified Neurotoxin complex as Headache Prophylaxis in Migraine Patients with 15 or More headache Days per 4-Week Period in a 24 week, Double-Blind, Randomized, Placebo Controlled, Parallel-Group Phase Followed by a 32 Week Open-Label Phase." Sub-Investigator 2006

- TRX103632/635 "A Randomized, Double-Blind, Multi-Center, Placebo Controlled, Cross-Over Study to Determine the Consistency of Response for TREXIMA (Sumatriptan 85mg/Naproxen Sodium 500mg) in the Acute Treatment of Multiple Migraine Attacks." Sub-Investigator 2006

- NL-2006-001 "A Phase III Randomized, Double-Blind, Parallel Group, Sham-Controlled Study Evaluating the Efficacy and Safety of Non-Invasive, Non-Repetitive Transcranial TMS Stimulation (TMS) for the Acute Preemptive Treatment of the Aura Phase of Migraine Headache." Sub-Investigator, 2007

- TRX106573 "A Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Cross-Over Study of Trexima® in Migraine Subjects Who Report Poor Response or Intolerance to Relpax®." Sub-Investigator, 2006

- TON/03/07-CLIN "A Multi-Centre, Parallel Group, Double-Blind, Placebo Controlled, Dose Ranging Study of the Efficacy and Tolerability of Tonabersat in the Prophylaxis of Migraine Headache and Open Label Extension." Sub-Investigator, 2007

- BTX0805 "Safety and Efficacy of Botulinum Neurotoxin Type A in the Treatment of Forward Head Posture with Associated Chronic Tension Type Headache using a Novel Fixed Site Injection Paradigm." Sub-investigator, 2009

- NXN-188-203 "A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache with Aura." Sub-Investigator, 2009

- NXN-188-204 "A Phase 2 Study of the Safety and Effectiveness of a Single Oral Dose of NXN 188 for the Treatment of Moderate to Severe Migraine Headache without Aura" – 2009

- 0462-082-00 " A Worldwide, Randomized, Double Blind, Placebo-Controlled, Parallel Group Clinical Trial to Evaluate the Safety and Efficacy of Rizatriptan for the Acute Treatment of Migraine in Children and Adolescents" - 2010

- COMPEL An open-label, multicenter study of the long-term efficacy, safety and tolerability of BOTOX for the prophylaxis of headaches in adult patients with chronic migraine. 2012

- ALD403-CLIN-011 A Parallel Group Double Blind Randomized Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients with Chronic Migraine. Sub-Investigator, 2018

- A Parallel Group Double-Blind Randomized Placebo- Controlled Study to Evaluate the Efficacy and Safety of Eptinezumab Administered Intravenously in Subjects Experiencing an Acute Attack of Migraine. Protocol Number ALD403-CLIN-015. Sub-Investigator – 2019

- M22-418: A Phase 3 Multicenter 24-Week Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Atogepant When Added to OnabotulinumtoxinA (BOTOX) for the Preventive Treatment of Chronic Migraine. Sub-Investigator – 2022

Multiple Sclerosis

- 9006- (TEVA) "A Multi-Center, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy, Tolerability, and Safety of 40mg of Copaxone in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients." Sub-Investigator, 2004
- A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5 mg and 1.25 mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis with optional extension phase Protocol No.: CFTY720D2309

- Extension to CFTY720D2309 (A 24-month double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 0.5mg and 1.25mg fingolimod (FTY720) administered orally once daily versus placebo in patients with relapsing-remitting multiple sclerosis, 2006

- 28821 "A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Trial of Oral Cladribine in Subjects with a First Clinical Event at High Risk of Converting to MS." – 2006

- CFTY720D2302 "A 12-Month Double-Blind, Randomized, Multi-Centre, Active-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of 0.5 mg and 1.25 mg Fingolimod (FTY720) Administered Orally Once Daily Versus Interferon β-1a (Avonex ®) Administered I.M. Once Weekly in Patients with Relapsing-Remitting Multiple Sclerosis". Principal Investigator, 2007

- MPB8298-SP-03 "A Double-Blind, Placebo Controlled Multi-Center Study to Evaluate the Efficacy and Safety of MBP8298 in Subjects with Secondary Progressive Multiple Sclerosis." Sub-Investigator, 2007

- ACT 10573 "A Double Blind, Placebo-Controlled, Randomized Crossover, Activity Study of Single Oral Doses of 50 mg and 400 mg Nerispirdine on Visual Function in Patients with Multiple Sclerosis." Sub-investigator, 2008

- DRI10566: "A 14-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Nerispirdine 50 mg, 100 mg, and 200 mg in Patients with Multiple Sclerosis." Sub-Investigator, 2009

- 29652 "A 12-week, Phase IIIb, Open-Label, Single-Arm, Multicenter Trial to Evaluate Ease of use of an Electronic Auto injector (RebiSmart™) for Self-Injection in Subjects with Relapsing Multiple Sclerosis (RMS) treated with Rebif® 44mcg Subcutaneously three times a week." Sub-Investigator, 2009

- Nerispirdine (HP184) - Clinical Trial - ACT10573: A double-blind, placebo-controlled, randomized crossover, activity study of oral doses of 50 mg and 400 mg nerispirdine on visual function in patients with multiple sclerosis, IND # 61,494." Sub-Investigator, 2009

- H9B-MC-BCDJ (a) –Multiple Subcutaneous Doses of LY2127399, an Anti-BAFF Human Antibody, in Subjects with Relapsing-Remitting Multiple Sclerosis." Sub-Investigator, 2009

- 101MS325 "A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects with Relapsing Remitting Multiple Sclerosis." Sub-investigator, 2010

- A 6-month, Randomized, Active Comparator, Open-label, Multi- Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod 0.5 mg/day in Patients with Relapsing Forms of Multiple Sclerosis who are candidates for MS therapy change from Previous Disease Modifying Therapy (EPOC)." Sub-Investigator, 2010

- EFC6058 "A multi-center double-blind parallel-group placebo-controlled study of the efficacy and safety of teriflunomide in patients with relapsing multiple sclerosis who are treated with interferon-beta." Sub-Investigator, 2010

- RebiDose Human Factors. A three-arm multicenter trial to preform human factors testing of the investigational RebiDose ready to use single use auto injector device including simulated injections in subjects with relapsing multiple sclerosis (RMS), caregivers, and nurses." Sub-Investigator, 2011

- RebiSmart Human Factors, A three-arm, multicenter trial to perform human factors testing of the investigational RebiSmart electronic auto-injector device including simulated injections in subjects with relapsing multiple sclerosis (RMS), caregivers, and nurses." Sub-Investigator, 2012

- FTY Prefer A 12-month, Prospective, Randomized, active-controlled, open label study to evaluate the patient retention of Fingolimod vs. approved first-line disease modifying therapies in adults who are in early stages of treatment for Relapsing Remitting multiple sclerosis." Sub-Investigator, 2012

- Novartis Assess FTY (2312): Fingolimod vs. Glatiramer Acetate A 12-month, randomized, rater and dose-blinded study to compare the efficacy and safety of fingolimod 0.25mg and 0.5mg administered orally once daily with glatiramer acetate 20mg administered subcutaneously once daily in patients with relapsing-remitting multiple sclerosis." Sub-investigator, 2012

- CFTY20D2399: "A Single arm, open-label, multi-center study evaluating the long-term safety and toleratbility of 0.5mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis." Sub-Investigator, 2013

- CBAF312A2304:" A multicenter, randomized, double-blind, parallel-group, placebo-controlled variable treatment duration study evaluating the efficacy and safety of Siponimod (BAF312) in patients with secondary progressive multiple sclerosis." Sub-Investigator 2014

- Biogen Idec 109MS413A multicenter, open-label phase IV study to evaluate whether a Medication Event Monitoring System (MEMS®) can improve adherence to Tecfidera® (delayed-release dimethyl fumarate) treatment in multiple sclerosis patient's Sub-investigator 2015

- Actelion AC-058B301 "Multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled, superiority study to compare the efficacy and safety of ponesimod to teriflunomide (Aubagio) in subjects with relapsing multiple sclerosis." Sub-Investigator 2015

- CHORDS, MN30035 An Open-Label Study To Evaluate The Effectiveness And Safety Of Ocrelizumab in Patients with Relapsing Remitting multiple Sclerosis Who Have Had A Suboptimal Response To An Adequate Course Of Disease-Modifying Treatment. Sub-Investigator, 2016

- Actelion AC-058B303 Multicenter, non-comparative extension to study AC-058B301, to investigate the long-term safety, tolerability, and control of disease of ponesimod 20mg in subjects with relapsing multiple sclerosis. Sub-investigator 2017

- TG1101-RMS301 Phase III: UbLiTuximab In Mutliple Sclerosis Treatment Effects (ULTIMATE I Study). Sub-investigator 2017

- ADAMAS ADS-AMTMS301– A 3-arm multicenter double blind placebo controlled randomized study to assess the efficacy and safety of ADS-5102 Amantadine extended release capsules in MS patients with walking impairment, ADS-AMT-MS301. Sub-Investigator 2018

- ABBVIE M14-397 – MS Safety and Efficacy study of Elezanumab (ABT-555) in Progressive Forms of MS. Sub-Investigator, 2018

- ABBVIE M18-918 – MS Safety and Efficacy study of Elezanumab (ABT-555) in Relapsing Forms of MS. Sub-Investigator, 2018

- BN42082: A phase IIIB multicenter, randomized double blind, controlled study to evaluate the efficacy, safety and pharmacokinetics of a higher dose of Ocrelizumab in adults with relapsing multiple sclerosis. Sub-Investigator - 2019

- GN41851. A phase III multicenter, randomized, double blind, double-dummy, parallel-group study to evaluate the efficacy and safety of Fenebrutinib compared with Teriflunomide in adult patients with relapsing Multiple Sclerosis. Sub-Investigator- 2020

- EFC17504: A randomized, double-blind, Phase 3 study comparing efficacy and safety of frexalimab (SAR441344) to placebo in adult participants with nonrelapsing secondary progressive multiple sclerosis. Sub Investigator – 2023

- EFC17919: Master protocol of two independent, randomized, double-blind, Phase 3 studies comparing efficacy and safety of frexalimab (SAR441344) to teriflunomide in adult participants with relapsing forms of multiple sclerosis. Sub Investigator – 2023

Parkinson's Disease

- RP 54274X-321 "A phase III multicenter, double blind, parallel-group placebo controlled study of the effect of Riluzole 50 mg BID or 100 mg BID on the progression of Parkinson's Disease in patients treated with L-Dopa or Dopamine Agonist." Sub-Investigator, 1999-2001

- 666E-CNS-0075-021 "A Phase III, Double-Blind, Placebo-Controlled, Randomized Study Comparing the Efficacy, Safety, and Tolerability of Sumanirole Versus Placebo or Ropinirole in Patients with Early Parkinson's Disease." Sub-Investigator, 2002-2003

- M/2760/0011 "PNU-95666E: Open-Label, Long Term, Flexible Dose Study of Safety, Tolerability and Therapeutic Response in Patients with Parkinson's Disease." Sub-Investigator, 2003

- DA2APD-0075-031 :A Phase III, Double-blind, Fixed Dose Response Study Comparing the Efficacy and Safely of Sumanirole vs. Placebo In Patients with Early Parkinson's Disease." Sub-Investigator, 2003

- 1198.100 NS2330 "A Fourteen-Week Placebo-Controlled Dose-Response Efficacy and Safety Study of NS 2330 in Early Parkinson's Disease Patients (Study for Proof of Concept in Early Parkinson's Disease of a Triple Reuptake Inhibitor, NS2330 / SCEPTRE)" Sub-Investigator, 2006

- S308-3-003 "A Multi-Centre, Randomized, Double-Blind, Parallel-Group Placebo and Pramipexole Controlled Study to Assess Efficacy and Safety of SLV308 Monotherapy in the Treatment of Patients with Early Stage Parkinson's Disease". Sub-Investigator, 2006

- S308-3-008 "An extension of SLV308, A multicenter, randomized, double-blind, parallel-group placebo and pramipexole controlled study to assess efficacy and safety of monotherapy in the treatment of patients with early stage Parkinson's disease." Sub-Investigator, 2007

- Droxidopa NOH306 "A Multicenter, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Study to Assess the Clinical Effect of Droxidopa in the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Parkinson's Disease." Sub-Investigator, 2010

- S187.3.002 "A Randomized, Double-Blind, Double-Dummy, Efficacy, Safety and Tolerability Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects Receiving Optimized Treatments with Parkinson Medicinal Products, who Continue to Experience Persistent Motor Fluctuations." Sub-Investigator, 2010

- S187.3.003 "Open-Label, 12-Month Safety and Efficacy Study of Levodopa – Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Disease Subjects." Sub-Investigator, 2010

- S187.3.004 "An Open-Label, 12 Month Safety and Efficacy Study of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Subjects with Advanced Parkinson's Disease and Severe Motor-Fluctuations Despite Optimized Treatment with Available Parkinson's Disease Medications." Sub-Investigator, 2010

- S187.3.005 "Open-Label Contiuation Treatment Study With Levodopa – Carbidopa Intestinal Gel In Subjects With Advanced Parkinson's Disease And Severe Motor-Fluctuation Who Have Exhibited A Persistent And Positive Effect To Treatment in Previous Studies." Sub-Investigator, 2010

- M12-920 "An Open-Label, Two Part, Multi-Center Study to Assess the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel (LCIG) for the Treatment of Non-Motor Symptoms in Subjects with Advanced Parkinson's Disease." Sub-Investigator, 2013

- A multicenter, randomized, active-controlled, double-blind, double-dummy, parallel group clinical trial, investigating the efficacy, safety, and tolerability of continuous subcutaneous ND0612 infusion in comparison to oral IR-LD/CD in subjects with Parkinson's disease experiencing motor fluctuateons (BouNDless) ND0612-317. Sub-Investigator – 2020

Stroke

- YM872 " A Randomized, Double-Blind, Placebo-Controlled, Sequential Dose-Escalation Study to Evaluate the Safety of YM872 in Patients with Acute Ischemic Stroke." 1998

- NF 198,003 "A double-blind, placebo-controlled, dose-ranging study of Nefiracetam in patients with Post-Stroke Depression." Sub-Investigator, 2001

- EFC7331 MATCH – "Management of Atherthrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack or Ischemic Stroke: A Randomized, Double-Blind Study, with 18 months of Follow-up." Principal Investigator, 2001-2002

- CHARISMA EFC4505 "Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA)." Sub-Investigator, 2002

- 981-124 "A Double-Blind, Randomized, Placebo-Controlled Study of Atorvastatin as Prevention of Cerebrovascular Events in Patients With a Previous Transient Ischemic Attack (TIA) or Stroke" Sub-Investigator, 2002

- Botox vs. Zanaflex "Placebo Controlled Trial of BOTOX ® versus Zanaflex ® for the Treatment of Subjects with Post- Stroke Upper limb Spasticity." Sub-Investigator, 2003

- 100282 Bayer Study "A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacolkinetic/Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients with Acute Ischemic Stroke." Sub-Investigator, 2003

- 9.159 "PRoFESS – Prevention Regimen for Effectively avoiding Second Strokes: A double-blind, active and placebo controlled study of Aggrenox vs. clopidogrel, with and without Micardis." Sub Investigator, 2004

- SA-NXY-0007: "A Double-Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke." Sub Investigator, 2004

- Ptcl-01213 Entitled: "A Randomized, Double-blind, Placebo-controlled, Multicenter, Parallel study to evaluate the effects of DP-b99 on Neurologic Function and Disability in subjects with Acute Ischemic Hemispheric Stroke." Sub-Investigator, 2004

- F7ICH-1641 A Randomized, Double-Blind, Placebo Controlled, Multi-Centre, Parallel Groups Confirmatory Efficacy and Safety Trial of Activated Recombinant Factor VII (NovoSeven®/Niastase® in Acute Intracerebral Hemorrhage." Sub-Investigator, 2005

- NTI-ASP-0502 "A Randomized, Double-Blind, Placebo Controlled Study of Ancrod (Viprinex) in Subjects Beginning Treatment within 6 Hours of the Onset of Acute Ischemic Stroke." Sub-Investigator, 2006

- CD-0125 "Safety and Efficacy of NeuroFlo Technology in Ischemic Stroke." Sub Investigator, 2006

- NTS-INT06-007 "A Double-Blind, Randomized, Controlled, Parallel Group, Multi-Centre, Pivotal Study to Assess the Safety and Effectiveness of the Treatment of Acute Ischemic Stroke with the NeuroThera® Laser System within 24 Hours from Stroke Onset." Sub-Investigator, 2007

- A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of SCH530348 in Addition to Standard of Care in Subjects with a History of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P - TIMI 50) P04737-3694." Sub-Investigator, 2007

- P04737 "A Multicenter, Randomized, Double-Blind, Placebo Controlled Study to Evaluate the Safety and Efficacy of SCH 530348 in Addition to Standard of Care in Subjects with a history of Atherosclerotic Disease: Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events." Sub-Investigator, 2008

- 01373 "A double blind, randomized, placebo-controlled, parallel group, multicenter Phase 3 pivotal study to assess the safety and efficacy of 1mg/kg/day intravenous DP-b99 over 4 consecutive days versus placebo when initiated within nine hours of acute ischemic stroke onset." Sub–Investigator, 2010

- NTS-INT08-009 " A double-blind, randomized, sham-controlled, parallel group, multicenter, pivotal study to assess the safety and efficacy of transcranial laser therapy with the NeuroThera® Laser System for the treatment of acute ischemic stroke within 24 hours of stroke onset." Sub–Investigator, 2010

- DALF-PS-1016 "A double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of two dose strengths of Dalfampridine extended release tablets for treatment of stable walking deficits in Post-Ischemic Stroke (MILESTONE)." Sub–Investigator, 2015-2017

- DALF-PS-1029 "An Extension Study to Evaluate the Long-Term Safety, Tolerability and Efficacy of Dalfampridine Extended-Release Tablets for the Treatment of Chronic Post-Ischemic Stroke Walking Deficits in Subjects Who Participated in the DALF-PS-1016 Study (MILESTONE)." Sub–Investigator, 2015-2018

- Abbvie M23-499 "A Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Efficacy, and Tolerability of ABBV-950 for the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients." Principal Investigator-2024

Other

- VA Cooperative Study 485 – National Health Survey of Gulf War Era Veterans and Their Families Clinical investigator for the neurologic aspect of the study (i.e. NCS and neurologic exams), 1997-2000

- E2020-A001-209 "A 12-week, multicenter, randomized, double-blind, placebo-controlled, preliminary study to determine the efficacy and safety of Donepezil Hydrochloride (E2020) in patients with persistent mild to moderate memory impairment resulting from a single Closed Head Injury." Sub-Investigator, 2001

- GAL-INT-11 "A randomized double blind placebo-controlled trial to evaluate the efficacy and safety of galantamine in subjects with mild cognitive impairment (MCI) clinically at risk for development of clinically probably Alzheimer's Disease." Sub-Investigator, 2001

- A1481066 – "A Multi-Center, Double-Blind, Placebo-Controlled Flexible Dose Study to Evaluate the Efficacy and Safety of Viagra ® in Women Who Have Female Sexual Arousal Disorder Resulting from a Traumatic Spinal Cord Injury." Sub-Investigator, 2003

- GAL-COG-3002- "An Analysis of Mortality in Subjects who participated in Three Studies of Galantamine in Mild Cognitive Impairment." Sub-Investigator, 2004

- 101468/205: A 12-Week, Double-Blind, Placebo Controlled, Parallel Group Study to Assess the Efficacy and Safety of Ropinirole XR (Extended Release) in Patients with Restless Legs Syndrome." Sub-Investigator, 2005

- E2020-A001-412: A One Year, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Efficacy and Safety of Donepezil Hydrochloride (E2020) in Subjects with Mild Cognitive Impairment." Sub-Investigator, 2005

- "A Randomized, Double-blind, Placebo Controlled Multi-Center Study to Evaluate the Safety and Efficacy of Botulinum Neurotoxin Type A in the Treatment of Forward Head Posture with Associated Chronic Tension Type Headache using a Novel Fixed Site Injection Paradigm" Sub-Investigator, 2009

- Alexion ECU-NMO-301: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Trial to Evaluate the Safety and Efficacy of Eculizumab in Patients with Relapsing Neuromyelitis Optica (NMO) Sub-Investigator 2014

- Alexion ECU-NMO-302: "A Phase III, Open-Label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients with Relapsing Neuromyelitis Optica (NMO)" Sub-Investigator 2014

- E2006-G000-304 A multicenter randomized double-blind placebo controlled active comparator parallel group study of the efficacy and safety of Lemborexant in Subjects 55 years and older with Insomnia Disorder. Sub-Investigator, 2016-2017

- INSIGHT-AHP: A Study to Characterize the Prevalence of Acute Hepatic Porphyria (AHP) in Patients with Clinical Presentation and History Consistent with AHP. Principal Investigator 2018-2019

- ALXN-1210-NMO-307: A phase 3, external placebo-controlled, open label, multicenter study to evaluate the efficacy and safety of Ravulizumab in adult patients with Neuromyelitis Optica Spectrum Disorder (NMOSD) Sub-Investigator – 2020

- KER2023.3 IMPACT: Investigating Mild cognitive impairment in Patients And Controls with TD-fNIRS Sub Investigator- 2023

- IMVT-1401-2401: A Phase 2b, Multi-center, Randomized, Quadruple-blind, Placebocontrolled Study of Batoclimab Treatment in Adult Participants with Active Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). Principal Investigator-2023

- IMVT-1401-3201: A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants with Active Thyroid Eye Disease (TED). Principal Investigator-2023

- R0000-CV-CES-2216: Prospective Assessment of Hemodynamics, Symptomatology, and Biochemical Markers of NPR1 Signaling in Patients with Postural Orthostatic Tachycardia Syndrome (POTS) and in Patients with Neurogenic Orthostatic Hypotension (nOH). Principal Investigator-2023

- APC-APN-305: Phase 3 randomized double-blind placebo-controlled 6-month parallel-arm study to compare a fixed dose combination of Aroxybutynin/Atomoxetine (AD109) to placebo in obstructive sleep apnea.. Sub Investigator - 2023